Anterior Pricing: What Health Plans Pay for Clinical Review AI

To the plan, on value with usage components. A value based model means the fee is negotiated against the administrative cost the plan expects to remove and, in some deployments, the medical expense effect, rather than against a seat count. The task fee per auto approved authorization is the usage layer: the plan pays when the system finishes a case without a human. Combined, the structure gives the vendor an incentive to maximise automated approvals within policy, and the plan an incentive to route more request types through the platform.

Two features distinguish it from the per member per month structures reported for Cohere Health. Task fees scale with volume rather than membership, which favours plans piloting narrow service lines, and the value component means the price is different for each plan and each use case, which is why nothing is published. For a plan, that makes benchmarking difficult and makes the definition of value and the audit rights the whole negotiation.

For a provider, the effect arrives indirectly. A platform paid per auto approved authorization is tuned to approve quickly where the record supports the policy, and to route to a human where it does not. Requests with complete clinical documentation should move faster; incomplete ones will not, and the difference is now determined by a model reading your packet rather than a nurse skimming it. The prior authorization automation use case explains what that does to the value of packet quality on your side.

A provider gets whatever the plan configures. Anterior is a review engine behind the plan's existing intake channels, so in most deployments you keep submitting through the plan's portal, your network or your EHR connection as before. What changes is decision speed and consistency for the service lines the plan has moved onto the platform. Anterior's site describes a Geisinger Health Plan deployment where cancer care approvals that took weeks now take about 155 seconds, a vendor figure quoted in MedCity News.

What costs you is the same as before, your own staff time and integration, with one addition. Where a model applies policy literally, the clinical evidence in your packet has to match the policy language explicitly, and practices that relied on a reviewer's judgement to fill gaps will see more requests routed for human review or additional information. That is a documentation cost, and it lands on clinicians and authorization staff rather than on a licence.

Provider side platforms such as Waystar and the free tiers of networks such as Availity are the tools that assemble and submit that packet, and their value rises as plan side review becomes more literal.

It competes with other plan side platforms, principally Cohere Health, and neither publishes a price. Cohere is reported to contract per member per month or per authorization; Anterior describes value based pricing with per auto approved authorization task fees. For a plan, the structural difference is where the risk sits: per member pricing is predictable and rewards scope expansion, task pricing tracks volume and rewards automation rate. A plan should model both against its authorization mix before choosing.

For a provider, comparing Anterior on price against anything you can buy is a category error. The relevant comparison is between the provider side tools that submit into plan platforms: Availity, whose Essentials portal is free and whose Essentials Plus tier is a vendor stated 25 USD a month, Waystar, which quotes against transaction volume, and Rhyme, which sells network connectivity. The prior authorization software comparison sets out which side each vendor serves.

For a health plan, the worth question is administrative cost per review and medical expense, and that analysis belongs on the plan side. For a provider, the useful question is whether a plan's deployment of Anterior changed your queue, and that is measurable. A worked example. An oncology group submits 400 authorizations a month to a plan that has moved cancer care review onto Anterior. Before the change, decisions took an average of nine days and staff spent 35 minutes per request across submission and follow up, about 233 hours a month.

If 70 percent of requests are now auto approved within minutes and follow up on those falls to five minutes, while the remaining 30 percent still take 35 minutes plus a further 20 minutes of documentation response, monthly staff time falls to roughly 133 hours, a saving of about 100 hours or 2,800 USD a month at a loaded 28 USD an hour, with faster treatment starts on top. If instead the auto approval rate for your service line is 30 percent and documentation requests rise, the saving can vanish. The figure to track is your own auto approval share by service line, and the prior authorization cost calculator gives you the before and after arithmetic. Where denials rise after a plan changes platform, the denial rate benchmark gives you the comparison to raise with the plan.

Your leverage is in the payer contract and the joint operating committee, not with Anterior. When a plan moves a service line onto an automated review platform, raise these points.

• Decision timeframes in writing, including for commercial lines outside CMS-0057-F, which requires impacted payers to decide standard requests within seven calendar days and expedited ones within 72 hours, as set out on our CMS prior authorization rule page.
• Published clinical criteria for each automated service line, so your packets match the policy language the model applies.
• Human review guarantees. A written commitment that adverse determinations are made by a qualified clinician, and the appeal route when a model routed the case.
• Auto approval and denial reporting by service line, so you can see what the platform is doing to your requests.
• Gold carding for providers with high approval rates.
• Submission channel. Acceptance of requests through the network or clearinghouse you already use, to avoid another portal.

None of that involves a licence fee. All of it changes your queue more than any tool you could buy.

Plan side automation changes what a good authorization packet looks like, and most provider organisations find out by watching their denial and pend rates move without knowing why. An independent review maps your payer mix against the review platforms in use, measures auto approval, pend and denial rates by plan and service line, and works out whether the fix is documentation, a submission tool or a payer negotiation. The three cost very different amounts, and the vendor market only sells one of them.

Clunic takes no commissions or referral fees from Anterior or any vendor. Our vendor selection service covers the provider side shortlist, and the AI readiness audit is the right starting point when the queue has changed and the cause is not yet quantified. Book a call if a plan has moved a service line onto automated review and your numbers moved with it.